ReviewMolecular biology reports2026
Targeting ferroptosis mediated cell death: a novel strategy for mitigating acute pancreatitis.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of a New, Potent, and Stable Tetrahydroquinoline-Based 5-LOX/sEH Dual Inhibitor with Polymodal Anti-Inflammatory Activity in Acute Pancreatitis.Journal of medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis (AP) is a common and potentially fatal inflammatory disorder characterized by pancreatic tissue inflammation and necrosis. Though our understanding of its pathogenesis has advanced, effective therapeutic approaches remain elusive, with many potential strategies still unexplored. Ferroptosis, an iron-dependent form of regulated cell death marked by the accumulation of lipid peroxides, plays a crucial role in tissue damage and inflammation. It has been implicated in various disorders, including neurodegenerative diseases like Alzheimer and Parkinson, ischemia-reperfusion injury, cancer, and other metabolic diseases. In AP, ferroptosis exacerbates disease progression by promoting pancreatic inflammation and cellular damage, thereby worsening clinical outcomes. However, its role in AP remains insufficiently explored due to the complexity of its molecular mechanisms and the limited availability of targeted interventions. This comprehensive review summarizes the factors involved in ferroptosis, such as glutathione depletion, defective lipid peroxide detoxification, dysregulation of iron homeostasis, and discusses established and emerging biomarkers. Furthermore, we discuss the FDA approved drugs and other investigational compounds targeting ferroptosis, along with the role of pro-inflammatory mediators, lipid peroxidation products, glutathione peroxidase 4 (GPX4), and iron regulatory proteins. The influence of PAMPs and DAMPs on ferroptosis signaling along with the potential role of epigenetic regulation is also highlighted. Overall, this review provides an integrated perspective on the role of ferroptosis in AP and emphasizes its potential as a novel therapeutic approach to mitigate AP. The goal is to use these insights into clinical practice to reduce the burden of this difficult condition.
Indexed as
Identifiers
41945254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.